Jennifer Somerfield et al.
Journal of immunology (Baltimore, Md. : 1950), 185(1), 763-768 (2010-06-04)
Biological therapies, even humanized mAbs, may induce antiglobulin responses that impair efficacy. We tested a novel strategy to induce tolerance to a therapeutic mAb. Twenty patients with relapsing-remitting multiple sclerosis received an initial cycle of alemtuzumab (Campath-1H), up to 120